当前位置: 首页 >> 检索结果
3222. Successful treatment of ANCA-associated glomerulonephritis following pulmonary alveolar proteinosis by rituximab and avacopan.
作者: Masanari Sugawara.;Arata Osanami.;Yuichiro Asai.;Yayoi Ogawa.;Ken Nagahata.;Hiroyuki Nakamura.;Chisako Suzuki.;Masatoshi Kanda.;Hiroki Takahashi.
来源: Rheumatology (Oxford). 2024年63卷2期e51-e52页 3223. Efficacy and management of tocilizumab in polymyalgia rheumatica: results of a multicentre retrospective observational study.
作者: Morgane Assaraf.;Baptiste Chevet.;Daniel Wendling.;Peggy Philippe.;Emeline Cailliau.;Christian Roux.;Philippe Dieude.;Sebastien Ottaviani.;Jérôme Avouac.;Mathilde Delacour.;Eric Houvenagel.;Jérémie Sellam.;Bernard Cortet.;Julien Henry.;René-Marc Flipo.;Valérie Devauchelle-Pensec.
来源: Rheumatology (Oxford). 2024年63卷8期2065-2073页
The efficacy of anti-IL-6 receptors such as tocilizumab (TCZ) was demonstrated in patients with PMR in two recent randomized controlled trials. The objective of this multicentre retrospective study was to assess the efficacy of TCZ in PMR patients requiring glucocorticoid (GC)-sparing treatment, as well as different strategies for TCZ withdrawal.
3225. Performance of GAP and ILD-GAP models in predicting lung transplant or death in interstitial pneumonia with autoimmune features.
作者: Michael R Allen.;Michail K Alevizos.;David Zhang.;Elana J Bernstein.
来源: Rheumatology (Oxford). 2024年63卷6期1568-1573页
To assess the ability of two risk prediction models in interstitial lung disease (ILD) to predict death or lung transplantation in a cohort of patients with interstitial pneumonia with autoimmune features (IPAF).
3226. Calprotectin: two sides of the same coin.
作者: Valeria Carnazzo.;Serena Redi.;Valerio Basile.;Patrizia Natali.;Francesca Gulli.;Francesco Equitani.;Mariapaola Marino.;Umberto Basile.
来源: Rheumatology (Oxford). 2024年63卷1期26-33页
Calprotectin (CLP) is a calcium-binding protein produced by neutrophils and monocytes in the course of inflammation. Today, the role of faecal CLP in chronic IBD is well known, but in recent years attention has shifted towards circulating CLP. In fact, this molecule can be measured in different biological fluids: blood, saliva and urine, using different analytic methods that are described in this review. Furthermore, different data confirm the relevant role of serum CLP in autoimmune diseases. In this review we will highlight the correlation between high levels of circulating CLP and specific autoantibodies of major autoimmune pathologies paving the way to the employment of CLP measurement as useful biomarker for monitoring outcome in different pathologies.
3228. Pregnancy outcomes in patients with familial Mediterranean fever: systematic review and meta-analysis.
作者: Yuhya Hirahara.;Midori Yamaguchi.;Kaoru Takase-Minegishi.;Yohei Kirino.;Shigeru Aoki.;Lisa Hirahara.;Soichiro Obata.;Michi Kasai.;Ayaka Maeda.;Naomi Tsuchida.;Ryusuke Yoshimi.;Nobuyuki Horita.;Hideaki Nakajima.;Etsuko Miyagi.
来源: Rheumatology (Oxford). 2024年63卷2期277-284页
The relationship between FMF and pregnancy outcomes remains unclear. This systematic review and meta-analysis aimed to clarify this association.
3229. Role of IL-6 and IL-6 targeted therapy in systemic lupus erythematosus.
Interleukin-6 (IL-6) is one of the cytokines implicated in murine and human SLE. Only a few small studies have investigated IL-6 inhibition in human SLE. Currently, there are no studies registered in clinicaltrials.gov to assess the IL-6 targeted therapy in SLE, yet its role in the future remains to be defined. This narrative review analyses these and potential areas of future studies with IL-6 targeted therapy in SLE.
3233. Health-related quality of life, remission and low lupus disease activity state in patients with systemic lupus erythematosus.
作者: Thomas Thibault.;Abdessamad Rajillah.;Abderrahmane Bourredjem.;Marie Corneloup.;François Maurier.;Denis Wahl.;Geraldine Muller.;Olivier Aumaitre.;Pascal Sève.;Gilles Blaison.;Jean-François Besancenot.;Thierry Martin.;Nadine Magy-Bertrand.;Maxime Samson.;Laurent Arnaud.;Zahir Amoura.;Hervé Devilliers.; .
来源: Rheumatology (Oxford). 2024年63卷5期1447-1455页
To measure the association between SLE remission and scores of patients-reported outcome (PRO) measures.
3235. Tofacitinib therapy in refractory inflammatory myositis: a retrospective cohort study of 41 patients.
作者: Madelaine Beckett.;Julia Tan.;Evelyne Bonnardeaux.;Jan Dutz.;Kamran Shojania.;Fergus To.;Anthony Obrzut.;J Aviña-Zubieta.;Kun Huang.
来源: Rheumatology (Oxford). 2024年63卷5期1432-1436页
To evaluate the efficacy and safety of tofacitinib in treatment-refractory inflammatory myositis in a real-world clinical setting.
3236. Pathogenetic associations of anti-ribosomal P protein antibody titres and their subclasses in patients with systemic lupus erythematosus.
作者: Yoshikatsu Kaneko.;Hiroe Sato.;Ayako Wakamatsu.;Daisuke Kobayashi.;Kaho Sato.;Yoichi Kurosawa.;Eriko Hasegawa.;Takeshi Nakatsue.;Takeshi Kuroda.;Ichiei Narita.
来源: Rheumatology (Oxford). 2024年63卷5期1411-1421页
We evaluated the association between anti-ribosomal P antibody (anti-RibP) titres and disease activity in Japanese SLE patients.
3237. Transcriptomic network analysis reveals key drivers of response to anti-TNF biologics in patients with rheumatoid arthritis.
作者: Chae-Yeon Yu.;Hye-Soon Lee.;Young Bin Joo.;Soo-Kyung Cho.;Chan-Bum Choi.;Yoon-Kyoung Sung.;Tae-Hwan Kim.;Jae-Bum Jun.;Dae Hyun Yoo.;Sang-Cheol Bae.;Kwangwoo Kim.;So-Young Bang.
来源: Rheumatology (Oxford). 2024年63卷5期1422-1431页
Anti-TNF biologics have been widely used to ameliorate disease activity in patients with RA. However, a large fraction of patients show a poor response to these agents. Moreover, no clinically applicable predictive biomarkers have been established. This study aimed to identify response-associated biomarkers using longitudinal transcriptomic data in two independent RA cohorts.
3238. Heart valve disease in primary antiphospholipid syndrome.
作者: Stanley Niznik.;Micha J Rapoport.;Orly Avnery.;Mona Kidon.;Ronen Shavit.;Martin H Ellis.;Nancy Agmon-Levin.
来源: Rheumatology (Oxford). 2024年63卷5期1397-1402页
APS-associated heart valve disease (HVD) is well described. Nonetheless, limited data exist on clinical parameters associated with the course of primary APS (pAPS) patients with HVD. The goal of this study was to assess clinical features and related outcomes in patients with APS-associated HVD.
3239. Autoantibodies against the melanoma differentiation-associated protein 5 in patients with dermatomyositis target the helicase domains.
作者: Eveline Van Gompel.;Deniz Demirdal.;Catia Fernandes-Cerqueira.;Begum Horuluoglu.;Angeles Galindo-Feria.;Edvard Wigren.;Susanne Gräslund.;Ellen De Langhe.;Olivier Benveniste.;Antonella Notarnicola.;Karine Chemin.;Ingrid E Lundberg.
来源: Rheumatology (Oxford). 2024年63卷5期1466-1473页
Clinical observations in patients with dermatomyositis (DM) and autoantibodies against the melanoma differentiation-associated protein 5 (MDA5) suggest that the autoantibodies contribute to the pathogenesis of MDA5(+) DM. To gain insight into the role of the anti-MDA5 autoantibodies, we aimed to identify their binding sites on the different domains of the MDA5 protein.
3240. Comparison of two frailty definitions in women with systemic lupus erythematosus.
作者: Sarah B Lieber.;Musarrat Nahid.;Alexandra Legge.;Mangala Rajan.;Robyn A Lipschultz.;Myriam Lin.;M Carrington Reid.;Lisa A Mandl.
来源: Rheumatology (Oxford). 2024年63卷5期1384-1390页
Frailty is a risk factor for adverse health in SLE. The Fried phenotype (FP) and the SLICC Frailty Index (SLICC-FI) are common frailty metrics reflecting distinct approaches to frailty assessment. We aimed to (1) compare frailty prevalence according to both metrics in women with SLE and describe differences between frail and non-frail participants using each method and (2) evaluate for cross-sectional associations between each metric and self-reported disability.
|